Cost‐Effectiveness and Cost‐Utility Analysis of Tongxinluo Capsules Compared With Conventional Therapy for the Treatment of Acute Myocardial Infarction
Year: 2025
Type: article
Abstract: AIM: Tongxinluo (TXL) capsule, a traditional Chinese medicine compound, has proven effective in acute myocardial infarction (AMI), but its cost-effectiveness is unclear. METHODS: This economic evaluation utilized individual data from clinical trials to compare major adverse cardiac and cerebrovascular events (MACCEs) at 30 days and quality-adjusted life years (QALYs) at 1 year between an intervention group (TXL combined with conventional therapy) and the control group (placebo plus conventional therapy), from a healthcare perspective. A lifetime cost-utility analysis (CUA) was conducted using a Markov model, and sensitivity analyses were performed to evaluate the robustness of the results. RESULTS: A total of 3777 patients (TXL: 1889; placebo: 1888) were included in the analysis. The 30-day total costs for the TXL and placebo groups were ¥38,561 ($5399) and ¥39,217 ($5490), respectively, showing no statistical difference. The 30-day MACCEs rates were 3.39% for the TXL group and 5.24% for the placebo group (p < 0.006), indicating TXL's superiority in effectiveness at 30 days. Over a lifetime, the TXL group incurred higher total costs (¥97,108 [$13,595] vs. ¥92,033 [$12,885]) and gained more QALYs (6.70 vs. 6.30). The incremental cost-effectiveness ratio for TXL was ¥12,421/QALY ($1739), below the 1 Gross Domestic Product per capital threshold which was ¥89,358 ($12,510) in 2023 in China. Sensitivity analysis confirmed robust results, revealing that TXL was more likely to be accepted over the placebo when the willingness to pay exceeds ¥12,500 ($1739). CONCLUSIONS: TXL is a cost-effective option compared to placebo in AMI.
DOI: 10.1111/jebm.70060
Authors: Guoqiang Liu, Peng Liu, Sijun Yu, Xia Liu, Fan Wang, Chunhui Liu, Xiaozhen Hu, Yongquan Jing, Linqiang Liu, Xuxia Zhang, Yuzeng Xue, Guanzhong Zheng, ChangYu Wang, Zhongming Zhao, Yanjie Zheng, Wenzhai Cao, Huanyi Zhang, Feng Gao, Jing Zhou, Zidong Bie, Guoqiang Yuan, Lei Wang, Jun Qian, Xiaochen Tian, Haitao Zhang, Xiangdong Li, Zhenhua Jia, Ningxin Ding, Yuejin Yang
Institutions: Hebei Medical University, Third Hospital of Hebei Medical University, Chinese PLA General Hospital, Chinese People's Liberation Army, Liaocheng People's Hospital, Central Hospital of Zibo, Shaanxi Provincial People's Hospital, Weihai Municipal Hospital, Zigong First People's Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Taian City Central Hospital, Fu Wai Hospital, Yanan University Affiliated Hospital, Yan'an University, Linyi People's Hospital, Hebei Yiling Hospital, Fourth People’s Hospital of Jinan, State Key Laboratory for Innovation and Transformation of Luobing Theory, Victoria University of Wellington, State Key Laboratory of Cardiovascular Disease
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: hybrid
Estimated APC paid: $2,550
OpenAlex ID: W4413270468